Literature DB >> 6829472

Long-term failure rate and morphologic correlations in porcine bioprosthetic heart valves.

F J Schoen, J J Collins, L H Cohn.   

Abstract

To ascertain relations among site, incidence, and mechanisms of clinically evident failure of porcine bioprosthetic heart valves, the frequency of failure of 1,110 valves in 1,001 adult operative survivors from January 1972 to January 1982 was reviewed and correlated with the pathologic features of 22 consecutive dysfunctional valves. There were 373 mitral, 519 aortic, and 109 double replacements, yielding for study 482 mitral and 628 aortic valves at risk. Infective endocarditis occurred in 1.9% (8 mitral, 7 aortic, and 4 double). Twenty-three valves (13 mitral and 10 aortic) with documented primary dysfunction were explanted, a mean of 55 months (range 9 to 94) after surgery. The primary dysfunction rate for the 333 valves implanted for greater than or equal to 5 years was 6.8% (11 of 161) for mitral and 4.1% (7 of 172) for aortic valves. Valves implanted for less than 5 years had a failure rate of 0.7%. The actuarially determined freedom from primary valve failure was 98 +/- 1% for mitral and 98 +/- 1% for aortic valves at 5 years and 79 +/- 7% for mitral and 91 +/- 4% for aortic valves at 10 years. Recovered valves (12 mitral and 10 aortic) with detailed morphologic analysis were functioning for a mean duration of 52 months (range 12 to 87). Causes of failure included calcification-related tears in 7 (4 mitral and 3 aortic, mean 66 months), tear without calcium deposits in 4 (4 mitral, mean 44 months), cuspal stiffening without tear but with calcium deposits in 2 (1 mitral and 1 aortic, mean 80 months) and thrombosis in 1 (aortic). Late primary dysfunction was most frequently a result of degenerative processes, especially calcification, often with secondary tears, but cuspal tears in the absence of calcium deposits and thrombosis predominated at shorter intervals.

Entities:  

Mesh:

Year:  1983        PMID: 6829472     DOI: 10.1016/s0002-9149(83)80173-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Calcification of subcutaneously implanted type I collagen sponges. Effects of formaldehyde and glutaraldehyde pretreatments.

Authors:  R J Levy; F J Schoen; F S Sherman; J Nichols; M A Hawley; S A Lund
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

2.  Mitral replacement: clinical experience with a ball-valve prosthesis. Twenty-five years later.

Authors:  A Cobanoglu; G L Grunkemeier; G M Aru; C L McKinley; A Starr
Journal:  Ann Surg       Date:  1985-09       Impact factor: 12.969

3.  Fifteen-year experience with 1678 Hancock porcine bioprosthetic heart valve replacements.

Authors:  L H Cohn; J J Collins; V J DiSesa; G S Couper; P S Peigh; W Kowalker; E Allred
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

4.  Calcific stenosis of a mitral valve xenograft in a patient in chronic renal failure.

Authors:  M J Raftery; G Koffman; J S Cameron
Journal:  Br Heart J       Date:  1989-08

5.  Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats.

Authors:  R J Levy; F J Schoen; J T Levy; A C Nelson; S L Howard; L J Oshry
Journal:  Am J Pathol       Date:  1983-11       Impact factor: 4.307

Review 6.  Bioengineering aspects of heart valve replacement.

Authors:  F J Schoen; J L Titus; G M Lawrie
Journal:  Ann Biomed Eng       Date:  1982       Impact factor: 3.934

7.  Double valve Implantation. Long-term evaluation of 8 different bioprostheses.

Authors:  P Stassano; V Mannacio; A Musumeci; A Golino; P Maida; V Ferrigno; G Buonocore; N Spampinato
Journal:  Tex Heart Inst J       Date:  1991

8.  Xenoantigenicity of porcine decellularized valves.

Authors:  Meghana R K Helder; Nicholas J Stoyles; Brandon J Tefft; Ryan S Hennessy; Rebecca R C Hennessy; Roy Dyer; Tyra Witt; Robert D Simari; Amir Lerman
Journal:  J Cardiothorac Surg       Date:  2017-07-17       Impact factor: 1.637

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.